Endotronix Receives Patent for Wireless Reading of Biosensor Implants

Endotronix patented wireless sensor and reader technology will revolutionize in‐home monitoring of heart failure patients, prevent hospital admissions, and improve the quality of patients’ lives.

Peoria, IL – Endotronix announced that the United States Patent and Trademark Office awarded Endotronix with U.S. Patent 8432265 for its wireless sensor reader. The patented technology is a key component of the Endotronix Heart Failure Monitoring solution that enables patients’ pulmonary artery pressure to be measured and read daily to predict and prevent worsening congestive heart failure (CHF).

“Our goal with the Endotronix solution is to proactively prevent costly CHF decompensation and hospital admissions from occurring in the first place,” said Endotronix Chief Medical Officer Nicolas Chronos, M.D. “It has been demonstrated that monitoring a patient’s pulmonary artery pressure on a daily basis and optimizing the patient’s treatment regimen prevents hospital readmissions and improves overall cardiac function.”

The innovative Endotronix solution is made up of three main hardware components: a small implantable sensor, a catheter delivery system, and a wireless reader that takes advantage of a narrow frequency band allowing it to be portable and affordable. The information generated through the hardware is transferred to a secure database and can be displayed within telehealth software for remote monitoring. “Utilizing cloud computing and clinically derived disease state management algorithms, health care providers can manage patients remotely in their homes and avoid unnecessary rehospitalizations,” said Dan Kendall, Vice President of Product Strategy at Endotronix.

The implant component that measures the pulmonary artery pressure is delivered to the artery via a minimally invasive, low risk, low cost catheterization. Unlike other monitoring solutions for heart failure patients, the small implant requires no batteries and does not puncture the patient’s vessels with leads, increasing its safety.

Core to the reader is the newly patented technology that enables a wireless device to read the implanted sensor and obtain the pressure reading. The patient captures this reading by holding the portable reader close to his / her chest one time a day for a few seconds. The reading is securely transmitted to the patient’s care record where it is monitored by care providers. This daily reading enables the care team to be proactive in optimizing the patient’s personal care plan to maintain healthy pressures and prevent a CHF incident.

“Endotronix’s unique wireless interrogation method allows us to use a simple and flexible reader unit that can take many forms, handheld or otherwise,” said Michael Nagy, Endotronix Vice President of Engineering. “It is the cornerstone of the company’s suite of safe, effective, simple, and affordable products for managing CHF at home, proactively and preventatively.”

While the initial focus for the Endotronix technology is on CHF, there are many places to measure pressure in the body, and therefore more clinical applications for their patented, proprietary technology.

CHF causes suffering, debilitation, and traumatic hospitalizations for more than 20 million people worldwide, and the associated costs amount to billions of dollars in annual spending. A CHF hospitalization typically requires an inpatient stay of between five to ten days and can cost up to $20,000 per event. However, hospitalizations only stabilize the patient temporarily and re-admissions frequently occur. Overall, the result is long-term deterioration of heart function and future hospitalizations are likely. Life expectancy and quality of life are significantly reduced. The Endotronix solution is the next generation of biosensor and telehealth technology designed to provide personalized care leading to improved patient outcomes and reductions to the overall cost of care.

About Endotronix
Endotronix (www.endotronix.com) develops digital health solutions with the goal of enhancing the quality of life, improving outcomes, and lowering costs, especially for the 20 million people worldwide who suffer from heart failure. Endotronix was founded in 2007 by Anthony Nunez, M.D., and mechanical engineer Harry Rowland, Ph.D. The company has a suite of technology patents supporting its innovative care management solutions. Endotronix is a privately funded company pursuing its CE Mark and European market introduction.

For more information about Endotronix, contact media@endotronix.com or G.A. Poole, -30- Agency at 630-473-3200 ext 201.